These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
239 related articles for article (PubMed ID: 33489083)
21. [Pimavanserin: a new treatment for the Parkinson's disease psychosis]. Duits JH; Ongering MS; Martens HJM; Schulte PFJ Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354 [TBL] [Abstract][Full Text] [Related]
22. Pimavanserin: novel pharmacotherapy for Parkinson's disease psychosis. Sahli ZT; Tarazi FI Expert Opin Drug Discov; 2018 Jan; 13(1):103-110. PubMed ID: 29047301 [TBL] [Abstract][Full Text] [Related]
23. Pimavanserin use in a movement disorders clinic: a single-center experience. Mahajan A; Bulica B; Ahmad A; Kaminski P; LeWitt P; Taylor D; Krstevska S; Patel N Neurol Sci; 2018 Oct; 39(10):1767-1771. PubMed ID: 30032332 [TBL] [Abstract][Full Text] [Related]
24. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905 [TBL] [Abstract][Full Text] [Related]
25. The safety, tolerability and efficacy of pimavanserin tartrate in the treatment of psychosis in Parkinson's disease. Hermanowicz S; Hermanowicz N Expert Rev Neurother; 2016 Jun; 16(6):625-33. PubMed ID: 26908168 [TBL] [Abstract][Full Text] [Related]
26. Screening, Diagnosis, and Management of Parkinson's Disease Psychosis: Recommendations From an Expert Panel. Pahwa R; Isaacson SH; Small GW; Torres-Yaghi Y; Pagan F; Sabbagh M Neurol Ther; 2022 Dec; 11(4):1571-1582. PubMed ID: 35906500 [TBL] [Abstract][Full Text] [Related]
30. Management of Parkinson's Disease Psychosis. Elsibai H; Kualleny M; Fandy TE Sr Care Pharm; 2022 Aug; 37(8):339-344. PubMed ID: 35879841 [No Abstract] [Full Text] [Related]
31. Mortality in Patients with Parkinson's Disease-Related Psychosis Treated with Pimavanserin Compared with Other Atypical Antipsychotics: A Cohort Study. Layton JB; Forns J; McQuay LJ; Danysh HE; Dempsey C; Anthony MS; Turner ME Drug Saf; 2023 Feb; 46(2):195-208. PubMed ID: 36517664 [TBL] [Abstract][Full Text] [Related]
32. Pimavanserin for the treatment of Parkinson's disease psychosis. Chendo I; Ferreira JJ Expert Opin Pharmacother; 2016 Oct; 17(15):2115-24. PubMed ID: 27609312 [TBL] [Abstract][Full Text] [Related]
33. Blinded SAPS-PD Assessment After 10 Weeks of Pimavanserin Treatment for Parkinson's Disease Psychosis. Isaacson SH; Coate B; Norton J; Stankovic S J Parkinsons Dis; 2020; 10(4):1389-1396. PubMed ID: 32716320 [TBL] [Abstract][Full Text] [Related]
34. Pimavanserin and Parkinson's Disease Psychosis: A Narrative Review. Rissardo JP; Durante Í; Sharon I; Fornari Caprara AL Brain Sci; 2022 Sep; 12(10):. PubMed ID: 36291220 [TBL] [Abstract][Full Text] [Related]
35. Evidence for using pimavanserin for the treatment of Parkinson's disease psychosis. Tampi RR; Tampi DJ; Young JJ; Balachandran S; Hoq RA; Manikkara G World J Psychiatry; 2019 Jun; 9(3):47-54. PubMed ID: 31211112 [TBL] [Abstract][Full Text] [Related]